Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inca00186
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
INCA00186 (uprevstobart) is a humanized monoclonal antibody that targets and inhibits CD73 (5'-ecto-nucleotidase; NT5E), an ectoenzyme involved in the production of immunosuppressive adenosine within the tumor microenvironment. By antagonizing CD73, INCA00186 reduces adenosine-mediated immunosuppression and enhances anti-tumor immune responses. It has been investigated as both monotherapy and in combination with other immunotherapies such as retifanlimab (anti-PD-1) and the A2A/A2B adenosine receptor antagonist INCB106385 for advanced solid tumors, including gastrointestinal cancers and squamous cell carcinoma of the head and neck. The drug was developed by Incyte[1][3][4][5][6][7].
- Brand names
- uprevstobart
02
Targets
NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on inca00186.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inca00186.